Myelodysplastic SyndromesAnemia, RefractoryAnemia, Refractory, with Excess of BlastsSyndromeLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, AcuteChromosomes, Human, Pair 5Leukemia, MyeloidAzacitidineAnemia, SideroblasticBone MarrowChromosome AberrationsKaryotypingMonosomyThalidomidePreleukemiaMyeloproliferative DisordersMyelodysplastic-Myeloproliferative DiseasesPancytopeniaAnemia, AplasticChromosomes, Human, Pair 7Cytogenetic AnalysisPrognosisBone Marrow CellsLeukemiaAcute DiseaseChromosome DeletionGranulocyte Precursor CellsTreatment OutcomeNeoplasms, Second PrimaryBone Marrow DiseasesHematopoietic Stem Cell TransplantationIron OverloadTrisomyAntimetabolites, AntineoplasticCytogeneticsErythrocyte TransfusionHematologic AgentsTransplantation, HomologousHematopoietic Stem CellsChelation TherapySurvival AnalysisAntigens, CD34ErythropoietinBlood TransfusionDown SyndromeCytarabineMetabolic Syndrome XRemission InductionBlast CrisisTransplantation ConditioningBone Marrow ExaminationThrombocytopeniaHematopoiesisBlood Cell CountMutationVidarabineSurvival RateSweet SyndromeIn Situ Hybridization, FluorescenceAnemia, MacrocyticGranulocyte Colony-Stimulating FactorHematologic DiseasesDisease ProgressionChromosomes, Human, Pair 8Antineoplastic AgentsCore Binding Factor Alpha 2 SubunitAnemiaChromosome DisordersHaploinsufficiencyRetrospective StudiesKaryotypeErythroid Precursor CellsTranslocation, GeneticChromosomes, Human, Pair 20Hematologic NeoplasmsPrimary MyelofibrosisIron Chelating AgentsHematinicsLeukemia, Myelomonocytic, AcuteFlow CytometryErythroid CellsBone Marrow TransplantationErythroblastsDNA Modification MethylasesHemoglobinuria, ParoxysmalImmunophenotypingRisk FactorsAntilymphocyte SerumBusulfanFatal OutcomeIsochromosomesHLA-DR Serological SubtypesRecurrenceMyeloid Progenitor CellsErythropoiesisRibonucleoprotein, U2 Small NuclearDNA Mutational AnalysisAntineoplastic Combined Chemotherapy ProtocolsThrombocytosis